Pficus De Med Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 16-11-2024
- Paid Up Capital ₹ 1.00 M
as on 16-11-2024
- Company Age 8 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 44.86%
(FY 2023)
- Profit 19.24%
(FY 2023)
- Ebitda 41.32%
(FY 2023)
- Net Worth 140.06%
(FY 2023)
- Total Assets 16.15%
(FY 2023)
About Pficus De Med
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Rameshkumar Jain, Sheetal Javerchand, Jitendra Jain, and One other member serve as directors at the Company.
- CIN/LLPIN
U74900KA2016PTC085780
- Company No.
085780
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Feb 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Pficus De Med?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jitendra Jain  | Managing Director | 03-Feb-2016 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Rameshkumar Jain | Director | 10-Mar-2016 | Current |
| Sheetal Javerchand | Director | 03-Feb-2016 | Current |
| Rikhabchand | Director | 10-Mar-2016 | Current |
Financial Performance of Pficus De Med.
Pficus De Med Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 44.86% increase. The company also saw a substantial improvement in profitability, with a 19.24% increase in profit. The company's net worth Soared by an impressive increase of 140.06%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pficus De Med?
In 2023, Pficus De Med had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Maxum Writing Instruments Private LimitedActive 6 years 5 monthsRameshkumar Jain is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Pficus De Med?
Pficus De Med has a workforce of 22 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pficus De Med, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pficus De Med's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
